NZ617376B2 - Rapid dissolve tablet compositions for vaginal administration - Google Patents
Rapid dissolve tablet compositions for vaginal administration Download PDFInfo
- Publication number
- NZ617376B2 NZ617376B2 NZ617376A NZ61737612A NZ617376B2 NZ 617376 B2 NZ617376 B2 NZ 617376B2 NZ 617376 A NZ617376 A NZ 617376A NZ 61737612 A NZ61737612 A NZ 61737612A NZ 617376 B2 NZ617376 B2 NZ 617376B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- agents
- pharmaceutical composition
- microgranules
- vaginal
- group
- Prior art date
Links
- 239000007916 tablet composition Substances 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims abstract description 109
- 239000003814 drug Substances 0.000 claims abstract description 92
- 229940079593 drugs Drugs 0.000 claims abstract description 86
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 29
- 239000000227 bioadhesive Substances 0.000 claims abstract description 26
- 239000007884 disintegrant Substances 0.000 claims abstract description 25
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 25
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 24
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical class O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims abstract description 22
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
- 210000004877 mucosa Anatomy 0.000 claims abstract description 17
- 238000003780 insertion Methods 0.000 claims abstract description 16
- 239000011230 binding agent Substances 0.000 claims abstract description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 13
- 229920003088 hydroxypropyl methyl cellulose Chemical class 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 claims abstract description 10
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical class N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims abstract description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 claims abstract description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 10
- 239000001866 hydroxypropyl methyl cellulose Chemical class 0.000 claims abstract description 10
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims abstract description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 150000007513 acids Chemical class 0.000 claims abstract description 9
- 229960003943 hypromellose Drugs 0.000 claims abstract description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 9
- 229920001661 Chitosan Polymers 0.000 claims abstract description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 7
- 229920002689 polyvinyl acetate Polymers 0.000 claims abstract description 7
- 239000011118 polyvinyl acetate Substances 0.000 claims abstract description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 7
- 229940113118 Carrageenan Drugs 0.000 claims abstract description 6
- 239000004952 Polyamide Substances 0.000 claims abstract description 6
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 6
- 239000000679 carrageenan Substances 0.000 claims abstract description 6
- 229920001525 carrageenan Polymers 0.000 claims abstract description 6
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 229920001577 copolymer Polymers 0.000 claims abstract description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 6
- 229920002647 polyamide Polymers 0.000 claims abstract description 6
- 239000011528 polyamide (building material) Substances 0.000 claims abstract description 6
- 239000000003 vaginal tablet Substances 0.000 claims abstract description 6
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 5
- 229920000591 gum Polymers 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 93
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims description 83
- 229960004556 Tenofovir Drugs 0.000 claims description 82
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- -1 immunosuppressives Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 25
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 25
- 229960000913 Crospovidone Drugs 0.000 claims description 24
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 24
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 24
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 23
- 239000000594 mannitol Substances 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 210000001215 Vagina Anatomy 0.000 claims description 16
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 15
- 238000007906 compression Methods 0.000 claims description 14
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 14
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims description 13
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 11
- 229940088597 Hormone Drugs 0.000 claims description 11
- 229960000282 Metronidazole Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 229960000366 emtricitabine Drugs 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 11
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 11
- 210000001519 tissues Anatomy 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims description 10
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 9
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 9
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims description 9
- 239000003903 antiretrovirus agent Substances 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 239000002777 nucleoside Substances 0.000 claims description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 9
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 9
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 claims description 8
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 8
- 239000003429 antifungal agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 229960004022 clotrimazole Drugs 0.000 claims description 7
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 7
- 239000003433 contraceptive agent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960003712 propranolol Drugs 0.000 claims description 7
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 6
- 230000000884 anti-protozoa Effects 0.000 claims description 6
- 239000002876 beta blocker Substances 0.000 claims description 6
- 230000001747 exhibiting Effects 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- FETSQPAGYOVAQU-UHFFFAOYSA-N Glyceryl palmitostearate Chemical class OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 5
- 208000005721 HIV Infections Diseases 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 229940035676 ANALGESICS Drugs 0.000 claims description 4
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 claims description 4
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 claims description 4
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 claims description 4
- 229960005475 Antiinfectives Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 4
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229940030606 DIURETICS Drugs 0.000 claims description 4
- JUZYLCPPVHEVSV-LJQANCHMSA-N Elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- 229940009714 Erythritol Drugs 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N Isomalt Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 claims description 4
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229940029983 VITAMINS Drugs 0.000 claims description 4
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 Xylitol Drugs 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 4
- 230000000202 analgesic Effects 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 230000003288 anthiarrhythmic Effects 0.000 claims description 4
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 4
- 230000003276 anti-hypertensive Effects 0.000 claims description 4
- 230000002924 anti-infective Effects 0.000 claims description 4
- 230000000111 anti-oxidant Effects 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- 230000002490 cerebral Effects 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229960003586 elvitegravir Drugs 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 4
- 230000000147 hypnotic Effects 0.000 claims description 4
- 239000003326 hypnotic agent Substances 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 4
- 235000010448 lactitol Nutrition 0.000 claims description 4
- 229960003451 lactitol Drugs 0.000 claims description 4
- 238000005461 lubrication Methods 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims description 4
- 230000002093 peripheral Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000001624 sedative Effects 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 229940026752 topical Sulfonamides Drugs 0.000 claims description 4
- 230000002936 tranquilizing Effects 0.000 claims description 4
- 239000003204 tranquilizing agent Substances 0.000 claims description 4
- 230000000261 vasodilator Effects 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamins Natural products 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- GWKIPRVERALPRD-ZDUSSCGKSA-N (S)-4-ISOPROPOXYCARBONYL-6-METHOXY-3-METHYLTHIOMETHYL-3,4-DIHYDROQUINOXALIN-2(1H)-THIONE Chemical compound N1C(=S)[C@H](CSC)N(C(=O)OC(C)C)C2=CC(OC)=CC=C21 GWKIPRVERALPRD-ZDUSSCGKSA-N 0.000 claims description 3
- SUPKOOSCJHTBAH-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 claims description 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N Amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 3
- RYMCFYKJDVMSIR-RNFRBKRXSA-N Apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 claims description 3
- 229950007936 Apricitabine Drugs 0.000 claims description 3
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 3
- MLILORUFDVLTSP-UHFFFAOYSA-N Emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims description 3
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 claims description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
- 229960000689 Nevirapine Drugs 0.000 claims description 3
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 3
- WHBIGIKBNXZKFE-UHFFFAOYSA-N Rescriptor Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
- 229960001852 Saquinavir Drugs 0.000 claims description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 3
- 229940083542 Sodium Drugs 0.000 claims description 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 3
- 229960004748 abacavir Drugs 0.000 claims description 3
- 229960001997 adefovir Drugs 0.000 claims description 3
- 229960001830 amprenavir Drugs 0.000 claims description 3
- 229960003277 atazanavir Drugs 0.000 claims description 3
- 229960004099 azithromycin Drugs 0.000 claims description 3
- 229960005107 darunavir Drugs 0.000 claims description 3
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 3
- 229960005319 delavirdine Drugs 0.000 claims description 3
- 229960003804 efavirenz Drugs 0.000 claims description 3
- 229960000980 entecavir Drugs 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 230000001506 immunosuppresive Effects 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229960000884 nelfinavir Drugs 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229920001888 polyacrylic acid Polymers 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229960000838 tipranavir Drugs 0.000 claims description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- ONBWNNUYXGJKKD-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;sodium Chemical class [Na].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC ONBWNNUYXGJKKD-UHFFFAOYSA-N 0.000 claims description 2
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims description 2
- 229960002682 Cefoxitin Drugs 0.000 claims description 2
- 229960004755 Ceftriaxone Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 229960003722 Doxycycline Drugs 0.000 claims description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- 229940067606 Lecithin Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229940067631 Phospholipids Drugs 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229940068965 Polysorbates Drugs 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical class CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002622 Triacetin Drugs 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- ZTBZARPZCHHXNW-UHFFFAOYSA-N dodecyl 2-hydroxybenzoate;sodium Chemical compound [Na].CCCCCCCCCCCCOC(=O)C1=CC=CC=C1O ZTBZARPZCHHXNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- HQSFGCUUTBCFPF-UHFFFAOYSA-N ethane-1,2-diol;octadecanoic acid Chemical compound OCCO.CCCCCCCCCCCCCCCCCC(O)=O HQSFGCUUTBCFPF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 150000007660 quinolones Chemical class 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229940044977 Vaginal Tablet Drugs 0.000 claims 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 2
- 239000002282 antimigraine agent Substances 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 229960002920 sorbitol Drugs 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
- 229940023040 Acyclovir Drugs 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 229960003580 Felodipine Drugs 0.000 claims 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- 229960000905 Indomethacin Drugs 0.000 claims 1
- 229940057948 Magnesium stearate Drugs 0.000 claims 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
- 229960002237 Metoprolol Drugs 0.000 claims 1
- 229960001783 Nicardipine Drugs 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 Nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 Oleate Drugs 0.000 claims 1
- 229940068977 Polysorbate 20 Drugs 0.000 claims 1
- 229940068968 Polysorbate 80 Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 Sulindac Drugs 0.000 claims 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229960004884 fluconazole Drugs 0.000 claims 1
- VUUGOXQPEXZJAE-UHFFFAOYSA-N hexadecanoic acid;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O VUUGOXQPEXZJAE-UHFFFAOYSA-N 0.000 claims 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229960004427 isradipine Drugs 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 1
- FSVSNKCOMJVGLM-UHFFFAOYSA-N octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O FSVSNKCOMJVGLM-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 claims 1
- 229960001179 penciclovir Drugs 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 1
- 229960001589 posaconazole Drugs 0.000 claims 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 238000004642 transportation engineering Methods 0.000 claims 1
- 229960001234 valaciclovir Drugs 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 238000005507 spraying Methods 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 17
- 239000002552 dosage form Substances 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 230000000699 topical Effects 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000008213 purified water Substances 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 10
- 229910001220 stainless steel Inorganic materials 0.000 description 10
- 239000010935 stainless steel Substances 0.000 description 10
- 201000009910 diseases by infectious agent Diseases 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000000798 anti-retroviral Effects 0.000 description 7
- 238000005243 fluidization Methods 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000029 vaginal gel Substances 0.000 description 5
- 102000033147 ERVK-25 Human genes 0.000 description 4
- 210000000987 Immune System Anatomy 0.000 description 4
- 229920003083 Kollidon® VA64 Polymers 0.000 description 4
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 4
- 230000003187 abdominal Effects 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 239000002850 integrase inhibitor Substances 0.000 description 4
- 239000004531 microgranule Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000001568 sexual Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229960001375 Lactose Drugs 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940032147 Starch Drugs 0.000 description 3
- 229940044950 Vaginal Gel Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000002440 hepatic Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000522 vaginal cream Substances 0.000 description 3
- 230000003612 virological Effects 0.000 description 3
- 239000007966 viscous suspension Substances 0.000 description 3
- DSSYKIVIOFKYAU-OIBJUYFYSA-N (S)-camphor Chemical compound C1C[C@]2(C)C(=O)C[C@H]1C2(C)C DSSYKIVIOFKYAU-OIBJUYFYSA-N 0.000 description 2
- YZHIXLCGPOTQNB-UHFFFAOYSA-N 2-METHYL-FURAN-3-CARBOTHIOIC ACID [4-CHLORO-3-(3-METHYL-BUT-2-ENYLOXY)-PHENYL]-AMIDE Chemical compound C1=C(Cl)C(OCC=C(C)C)=CC(NC(=S)C2=C(OC=C2)C)=C1 YZHIXLCGPOTQNB-UHFFFAOYSA-N 0.000 description 2
- 229940035674 ANESTHETICS Drugs 0.000 description 2
- 229940036592 ANTHELMINTICS Drugs 0.000 description 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 229940005486 ANTIMIGRAINE PREPARATIONS Drugs 0.000 description 2
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 2
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 229940037530 COUGH AND COLD PREPARATIONS Drugs 0.000 description 2
- 206010058019 Cancer pain Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101700020566 DEFA4 Proteins 0.000 description 2
- 206010061428 Decreased appetite Diseases 0.000 description 2
- 206010067647 Delivery Diseases 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 210000004392 Genitalia Anatomy 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 2
- FBPFZTCFMRRESA-BXKVDMCESA-N L-mannitol Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO FBPFZTCFMRRESA-BXKVDMCESA-N 0.000 description 2
- 206010025482 Malaise Diseases 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 101710008205 OXT Proteins 0.000 description 2
- 102100017240 OXT Human genes 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229960001723 Oxytocin Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229940005542 PARASYMPATHOMIMETICS Drugs 0.000 description 2
- 206010057190 Respiratory tract infection Diseases 0.000 description 2
- 206010040490 Sexually transmitted disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 229940064707 Sympathomimetics Drugs 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229940053550 agents used for ADHD and nootropics psychostimulants Xanthine derivatives Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 230000000578 anorexic Effects 0.000 description 2
- 230000000507 anthelmentic Effects 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 230000002456 anti-arthritic Effects 0.000 description 2
- 230000001078 anti-cholinergic Effects 0.000 description 2
- 230000001773 anti-convulsant Effects 0.000 description 2
- 230000001430 anti-depressive Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000000118 anti-eoplastic Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001139 anti-pruritic Effects 0.000 description 2
- 230000000561 anti-psychotic Effects 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- 230000002921 anti-spasmodic Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940006131 antiglaucoma preparations and miotics Parasympathomimetics Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002579 antinauseant Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000000975 bioactive Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009506 drug dissolution testing Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 229940083747 low-ceiling diuretics Xanthine derivatives Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003641 microbiacidal Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000003232 mucoadhesive Effects 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 101700057139 oxyT Proteins 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000002445 parasympatholytic Effects 0.000 description 2
- 230000001499 parasympathomimetic Effects 0.000 description 2
- 239000000734 parasympathomimetic agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001975 sympathomimetic Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- FQRHOOHLUYHMGG-WLHGVMLRSA-N (E)-but-2-enedioic acid;1-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]ethanone Chemical compound OC(=O)\C=C\C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-WLHGVMLRSA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 229960001946 Acepromazine Maleate Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229940062527 Alendronate Drugs 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 Bromocriptine Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N Butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960001113 Butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 Chlorpromazine Drugs 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N Cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229950006497 Dapivirine Drugs 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N Dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001193 Diclofenac Sodium Drugs 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N Dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 229940028937 Divalproex Sodium Drugs 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 229960000394 Droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N Droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N Eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- BOLCFGMGGWCOOE-CTTKVJGISA-N Ergostine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@@H]1C=C2C=3C=CC=C4NC=C(C=34)C[C@H]2N(C)C1)CC)C1=CC=CC=C1 BOLCFGMGGWCOOE-CTTKVJGISA-N 0.000 description 1
- 229960004943 Ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N Ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000000801 Human immunodeficiency virus 1 reverse transcriptase Human genes 0.000 description 1
- 108010001522 Human immunodeficiency virus 1 reverse transcriptase Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 229940015872 Ibandronate Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229950006971 Incadronic acid Drugs 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N Incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- XVQUOJBERHHONY-UHFFFAOYSA-N Isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- FFVXQGMUHIJQAO-BFKQJKLPSA-N Levonantradol Chemical compound C([C@@H](C)OC=1C=C(OC(C)=O)C=2[C@@H]3C[C@H](O)CC[C@H]3[C@H](C)NC=2C=1)CCC1=CC=CC=C1 FFVXQGMUHIJQAO-BFKQJKLPSA-N 0.000 description 1
- 229950005812 Levonantradol Drugs 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N MDL-62769 Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- 229940041655 Meperidine Drugs 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N Minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N Nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N Naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N RIFAXIMIN Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229940089617 Risedronate Drugs 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229960003708 Sumatriptan Drugs 0.000 description 1
- GKZARTFJSANTLY-UHFFFAOYSA-N Sumatriptan Chemical compound [CH]1C(CS(=O)(=O)NC)=CC=C2N=CC(CCN(C)C)=C21 GKZARTFJSANTLY-UHFFFAOYSA-N 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940019375 Tiludronate Drugs 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 230000036201 Tissue concentration Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N Tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 240000002913 Trifolium pratense Species 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N Zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001195 anabolic Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000002460 anti-migraine Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002567 autonomic Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical class CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 210000003702 immature single positive T cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960003046 isometheptene Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000009481 moist granulation Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Chemical class 0.000 description 1
- 239000005017 polysaccharide Chemical class 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- 229960002814 rilpivirine Drugs 0.000 description 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- ZUWVVMMRNQEJMW-WGAVTJJLSA-N sodium;[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methoxysulfonylazanide Chemical compound [Na+].C1O[C@@]2(COS([NH-])(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 ZUWVVMMRNQEJMW-WGAVTJJLSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Provided are pharmaceutical compositions for vaginal administration and methods of preparing them. The compositions are in the form of rapid dissolve vaginal tablets .The compositions comprise rapid dissolve microgranules comprising: (a) a therapeutically effective amount of a vaginally active drug; (b) a polymeric excipient having a dual property of acting as a binder as well as a bioadhesive material; (c) a sugar alcohol, a saccharide, or a mixture thereof; and (d) a disintegrant; wherein said pharmaceutical composition rapidly disintegrates upon insertion into the vaginal cavity of a patient or subject forming a viscous drug-containing suspension that rapidly, widely spreads coating the vaginal mucosa. Examples of the polymeric excipient include low-substituted hydroxyethylcellulose, hydroxypropylcellulose, hypromellose, polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone-polyvinyl acetate copolymer, ethylene glycol 6000 - vinylcaprolactam - vinyl acetate copolymer, polyvinyl alcohol, polyethylene oxide, poly(lactic co-glycolic acid), polyamide, alginic acid salts, carrageenan, chitosan, and cellulosic gum. g; (b) a polymeric excipient having a dual property of acting as a binder as well as a bioadhesive material; (c) a sugar alcohol, a saccharide, or a mixture thereof; and (d) a disintegrant; wherein said pharmaceutical composition rapidly disintegrates upon insertion into the vaginal cavity of a patient or subject forming a viscous drug-containing suspension that rapidly, widely spreads coating the vaginal mucosa. Examples of the polymeric excipient include low-substituted hydroxyethylcellulose, hydroxypropylcellulose, hypromellose, polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone-polyvinyl acetate copolymer, ethylene glycol 6000 - vinylcaprolactam - vinyl acetate copolymer, polyvinyl alcohol, polyethylene oxide, poly(lactic co-glycolic acid), polyamide, alginic acid salts, carrageenan, chitosan, and cellulosic gum.
Description
RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATION
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims priority to U.S. Application Ser. No. 61/481,582 filed
May 2, 2011, which is incorporated by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
Vaginal drug delivery is a potential route for therapy via topical action or systemic
absorption as well as uterine targeting of active pharmaceutical ingredients. It offers advantages
such as:
large surface area
avoiding hepatic first-pass effect, which may result in significant enhancement of
bioavailability or reduction in dose strength or side-effect profile
dense network of blood vessels
high permeability even for large molecular weight drugs such as peptides and
proteins
low systemic drug exposure (namely in the case of products used for local
conditions)
low enzymatic activity and the possibility of preferential transfer of absorbed
drugs to the uterus (referred to as the “first-uterine-pass effect”)
ease of removal in case of necessity
Despite these advantages, the intravaginal route of administration for drug delivery has
been exploited only to a limited extent. Vaginal drug delivery systems such as conventional
206449NZ_spec_20160212_PLH
tablets are traditionally used to deliver contraceptives and microbicides to treat vaginal infection.
Vaginal tablets, rings, creams, and viscous gels containing a wide range of drugs (e.g., steroids,
prostaglandins, antimicrobials, proteins, and peptides) have been developed, and in vitro, ex vivo,
and in vivo performance evaluations of these vaginal drug delivery systems have been studied.
Studies of intravaginal drug delivery systems such as these comprising one or more nontoxic,
nonirritant, or bioadhesive materials that are easy to incorporate into vaginal dosage forms and
which, in theory, could extend the bioactive residence time within the vagina and reduce the
dosing frequency as well as the dose administered include: Lehr, 2000. J. Control. Rel. 65, 19-
29; Mandal et al. 2000. J. Pharm. Biopharm. 50, 337-343; Garg et al., 2001. Pharma. Tech. 14-
23; Ceschel et al., 2001. Drug Del. Ind. Pharm. 6, 541-547; Bilensoy et al., 2006. AAPS
PharmSciTech. 7, 19-29; Valenta, 2005. Advanced Drug Del. Rev. 57, 1692-1712; Bonferoni et
al., 2006. AAPS Pharm. SciTech. 7, E1-E8; Neves et al., 2008. Eur. J. Pharm. Biopharm. 69,
622-632; Ndesendo et al., 2009. Int. J. Pharm. 370, 151-159; Poelvoorde et al., 2009. J. Pharm.
Biopharm. 71, 280343; Perioli et al., 2009. Int. J. Pharm. 377, 120-127; Yellanki et al.,
2010. Int. J. PharmTech Res. 2; 1746-1750; and Wang et al., 2002. J. Contr. Rel. 82, 39-50.
A vast majority of bioadhesive gels, creams, and tablets that are used as vaginal delivery
systems break down rapidly following application into the vaginal cavity and have minimal
bioadherence to the vaginal mucosa. These complications are likely due to miscibility with
water or due to a lack of physical stability at body temperature, such that only a limited
therapeutic effectiveness is exhibited. Emulsion based vaginal drug delivery systems have been
developed, such as ones containing (i) one or more globule stabilizing polymers (e.g., HPMC,
polyvinyl alcohol, or a PEGylated lipid) and (ii) a therapeutically active drug; drugs approved for
or used for the treatment, prophylaxis, cure, or mitigation of diseases of the vagina, urinary tract,
cervix, or other female reproductive organ; inducement of contraception; or systemic drug
therapy.
US 20030180366 (US 6,899,890) discloses a novel, microemulsion based, essentially pH
neutral, vaginal drug delivery system suitable for modified delivery of a therapeutically active
material in the vaginal cavity. US 20050276836 discloses a method of coating a vaginal device
206449NZ_spec_20160212_PLH
for delivering therapeutic or health-promoting agents with a mucoadhesive composition. WO
2008133928 discloses a method of treating a patient having an epithelial lesion, such as of the
vagina, or disorder of impaired mucin function as well as methods of treating pain associated
with epithelial lesions and disorders of impaired mucin function using a pharmaceutical
composition containing mucin glycoproteins in combination with therapeutic agents, e.g., trefoil
polypeptides. WO 2010061284 discloses a controlled release, intravaginal, pharmaceutical
dosage form consisting of at least one pharmaceutically active ingredient which is admixed with
a combination of biocompatible and biodegradable polymers and shaped for insertion into the
vagina of a patient. The vaginal administration of a controlled-release opioid such as oxycodone
has been shown to be a safe, effective, and simple means of managing cancer pain in patients
who cannot tolerate the adverse events caused by oral administration (X. Zhang, X-J. Ruan, C.
Liu, and Z-H. Yu, Effect of vaginal administration of controlled-release oxycodone on cancer
pain. Chin. J. Cancer J. Cancer, 2009, 28(7) 1-4; F. Acartürk, Mucoadhesive Vaginal Drug
Delivery Systems. Recent Patents on Drug Delivery & Formulation 2009, 3, 193-205)
(“Acartürk 2009”). Acartürk 2009 recently summarized the development and in vitro/in vivo
evaluations of improved formulations for transmucosal vaginal delivery.
Disintegration or distribution/spreading, as well as retention time of bioadhesive vaginal
dosage forms (e.g., conventional tablet, multiparticulate, viscous gel formulations), have been
evaluated extensively. Conventional or even bioadhesive vaginal tablets are easy to administer
in privacy by the user; however these dosage forms may be too slow to disintegrate and spread
and are cleared from the vagina too rapidly to provide any meaningful improvement in therapy.
The level of patient compliance is poor and is generally believed to be influenced by restrictive
dosing regimens, a need to consume multiple combination oral drug products, patients'
suspicions as to the effectiveness of vaginal therapy, leakage, or discomfort associated with
administration. Furthermore, gel dosage forms require the use of a vaginal applicator, thereby
resulting in increased packaging materials and manufacturing costs.
One area where vaginal administration has been explored is in the context of the
treatment of acquired immune deficiency syndrome (AIDS), as the impact of human
206449NZ_spec_20160212_PLH
immunodeficiency virus (HIV) continues to significantly affect large numbers of worldwide
populations. HIV is a retrovirus that primarily infects and directly and indirectly destroys vital
components of the human immune system such as CD4 T cells (a subset of T cells that are
required for the proper functioning of the human immune system), macrophages, and dendritic
cells. AIDS is a collection of symptoms and infections resulting from specific damage to the
immune system caused by HIV in humans. AIDS acquired via sexually transmitted infections
(STIs) affect more than 13 million men and women in the USA every year. Although treatments
for AIDS and HIV exist to decelerate the virus’ progression, there is currently no known cure.
Despite a recent report from the Joint United Nations Program on HIV/AIDS (UNAIDS/WHO
2008 – Report on the Global AIDS Epidemic. Geneva: UNAIDS, p. 362) claiming the HIV
epidemic has stabilized, this past year saw 2.7 million new infections of HIV-1 infection and 2
million more perished.
In patients infected by HIV, the efficacy of highly active antiretroviral (ARV) therapy
through the blockade of different steps of the retrovirus life cycle is now well understood. As
HIV is a retrovirus that replicates within cells of the immune system, intracellular drug
concentrations are important to determine ARV drug efficacy and toxicity. Some ARV agents
used for oral administration are prodrugs that require intracellular anabolic phosphorylation to be
converted to their active form of triphosphorylated metabolites. The active metabolites, which
have longer plasma half-lives than their parent compounds, have been used in the vaginal route
of administration.
Some studies in the area of vaginal administration and HIV therapy include the
following. In vitro and ex vivo testing of tenofovir (TFV) as a vaginal gel formulation containing
1% TFV and 2% hydroxyethylcellulose (HEC) as a bioadhesive polymer was shown by in vitro
and ex vivo testing to be as effective as an HIV-1 microbicide (Mayer et al., 2006. AIDS. 20,
543-551; Rohan et al., PLoS One Feb 2010. 5, 1-12). New generations of vaginal gels
comprising 1% TFV in combination with 5% emitricitabine (FTC) provided protection from
Simian HIV exposures in Macaques (Parikh et al., 2009. J. Virology. 83, 10358-10364). The
results of studies using (i) dual segment polyurethane vaginal rings sustaining the release of two
206449NZ_spec_20160212_PLH
oral antiretroviral agents, tenofovir and dapivirine, or (ii) vaginal gels containing a
thiocarboxanilide UC781, were investigated for antiretroviral activities (Friend, 2000. Pharm.
Develop. Technol. 1-20; Mahalingam et al., 2010. Pharm. Res. 27, 2478-2491).
Despite the promising characteristics of the vagina for drug therapy, development and
commercialization issues persist, such as:
lack of appropriate in vitro/ex vivo test methods
lack of adequate retention time of the vaginal formulation
lack of adequate spreading characteristics of the vaginal formulation
other limitations include menstrual cycle-associated vaginal changes, genital
hygiene issues, local side effects, coitus interference and variable drug
permeability
social taboos, unawareness, and gender-specificity are also strong barriers to the
use and development of vaginal drug delivery
lack of vaginal formulations having an ease of administration without causing
discomfort to improve patient compliance.
The present inventors surprisingly found a way to provide a vaginal dosage form, a ‘rapid
dissolve tablet formulation,’ which promises to meet the unmet medical need for a vaginal
dosage form that is easy to administer in privacy and which rapidly disintegrates/dissolves upon
insertion into the vaginal cavity. This dosage form creates a viscous suspension that is spread
rapidly and widely over the vaginal mucosa and is retained for a sufficiently long time to provide
therapeutic efficacy via topical action or systemic absorption. Unlike the gel dosage form, use of
a vaginal applicator is not required for these tablets, thereby making them an attractive dosage
form based on potential reductions in packaging materials (i.e., increased portability) and
manufacturing costs. This dosage form may be used in the context of HIV therapy as well as
other therapeutic applications.
206449NZ_spec_20160212_PLH
SUMMARY OF THE INVENTION
In some embodiments, this invention relates to rapid dissolve tablet compositions
comprising one or more active pharmaceutical ingredients for the treatment of disease states via
topical action or systemic absorption upon vaginal administration, and methods of making and
using such compositions.
In some embodiments, this invention relates to pharmaceutical compositions comprising
one or more active pharmaceutical ingredients suitable for vaginal route of administration, and
methods of making and using such compositions for therapy via topical action or systemic
absorption, as well as uterine targeting. In certain embodiments, the present invention is related
to a pharmaceutical composition comprising one or more active pharmaceutical ingredients
suitable for vaginal route of administration, one or more polymeric excipients having a dual
property of acting as a binder as well as a bioadhesive material, one or more sugar alcohols or
saccharides, and one or more disintegrants, which rapidly disintegrates in the vaginal cavity
forming a viscous suspension that rapidly and widely spreads to coat the vaginal mucosa with the
drug suspension/solution for therapy via topical action or systemic absorption.
The pharmaceutical composition of the present invention may contain at least one drug
selected from the group consisting of antifungal agents; antibacterial agents; antimicrobial
agents; antiviral agents; anti-infectives; spermicides; hormones; antibiotics; antiviral agents;
analgesics; antitrichomonial agents; antiprotozoan agents; antimycoplasm agents; antiretroviral
agents; nucleoside analogues; reverse transcriptase inhibitors; protease inhibitors; contraceptive
agents; anorexics and appetite suppressants; steroids; anthelmintics; anesthetics; antiarthritics;
antiasthma agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals;
antihistamines; anti-inflammatory agents; antimigraine preparations; antimotion sickness agents;
antinauseants; antineoplastics; antiparkinsonism agents; antipruritics; antipsychotics;
antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives;
cardiovascular preparations; calcium channel blockers; beta blockers; antiarrhythmics;
antihypertensives; diuretics; general, coronary, peripheral and cerebral vasodilators; erectile
dysfunction agents; central nervous system stimulants; cough and cold preparations;
206449NZ_spec_20160212_PLH
decongestants; diagnostics; hormones; hypnotics; immunosuppressives; muscle relaxants;
parasympatholytics; parasympathomimetics, psychostimulants, sedatives, orally active drugs
exhibiting significant first-pass effects; proteins/peptides including growth enhancing hormones
and luteinizing-hormone-releasing hormone (LHRH); tranquilizers; antioxidants; vitamins;
minerals; and herbal extracts or preparations, or combinations thereof, for vaginal administration.
According to the invention, the bioadhesive property of the polymer excipient (e.g., low-
substituted hydroxyethylcellulose, hydroxypropylcellulose, hypromellose, polycarboxylic acids,
polyvinylpyrrolidone, vinylpyrrolidone-polyvinyl acetate copolymer, ethylene glycol 6000 -
vinylcaprolactam - vinyl acetate copolymer, polyvinyl alcohol, polyethylene oxide, poly(lactic
co-glycolic acid), polyamide, alginic acid salts, carrageenan, chitosan, and cellulosic gum) will
enhance bioadherence of the active ingredient (drug) to the mucosa surface, thereby increasing
the retention time for improved therapy via topical action or systemic absorption.
In certain embodiments, wherein the pharmaceutical composition could further comprise
a surfactant, and/or a lipid that will enhance bioadherence of the active ingredient to the mucosa
surface or enhance/sustain systemic absorption, thereby providing improved therapy via topical
action or systemic absorption, and reduced side effects; more particularly when the drug has poor
water solubility.
In some other embodiments, the present invention is directed to a pharmaceutical
composition in the form of a rapid dissolve tablet, which rapidly disintegrates upon insertion into
the vagina of a patient, forming a viscous suspension that rapidly and widely spreads and coats
the vaginal mucosa with the drug suspension/solution for therapy via topical action or systemic
absorption.
Yet in some other embodiments, the present invention is related to a rapid dissolve tablet
comprising rapidly dispersing microgranules comprising at least one sugar alcohol and at least
one disintegrant. This tablet may rapidly disintegrate upon insertion into the vagina of a patient,
forming a viscous drug suspension that rapidly and widely spreads to coat the vaginal mucosa
with the drug suspension/solution.
206449NZ_spec_20160212_PLH
BRIEF DESCRIPTION OF THE DRAWINGS
shows a schematic of a ‘Rapid Dissolve Tablet’ as conceived in certain
embodiments of the present invention.
shows mean tenofovir plasma concentration – time profiles following vaginal
administration of a single tenofovir rapid dissolve tablet (RDT) in female rabbits.
shows mean tenofovir plasma concentration – time profiles following a multi-dose
(7 once-daily dosing) administration of tenofovir rapid dissolve tablets (RDTs) into the vagina of
female rabbits.
shows mean free and total tenofovir contents of the abdominal and vaginal tissues
at 2 and 24 hrs post dosing following vaginal administration of a single tenofovir rapid dissolve
tablet (RDT) in female rabbits.
shows mean free and total tenofovir contents of the abdominal and vaginal tissues
at 2 and 24 hrs post dosing following a multi-dose (7 once-daily dosing) administration of
tenofovir rapid dissolve tablets (RDTs) into the vagina of female rabbits.
shows mean predose and postdose tenofovir concentrations in Weck-Cel at 2 and
24 hrs post dosing following vaginal administration of a single tenofovir rapid dissolve tablet
(RDT) in female rabbits.
shows mean predose and postdose tenofovir concentrations in Weck-Cel at 2 and
24 hrs post dosing following a multi-dose (7 once-daily dosing) administration of tenofovir rapid
dissolve tablets (RDTs) into the vagina of female rabbits.
DETAILED DESCRIPTION OF THE INVENTION
The following description includes information that may be useful in understanding the
invention. It is not an admission that any of the information provided herein is prior art or that
any publication specifically or implicitly referenced is prior art.
206449NZ_spec_20160212_PLH
All documents cited herein are incorporated by reference in their entirety for all purposes
to the same extent as if each individual document was specifically and individually indicated to
be incorporated by reference. As used above, and throughout the description of the invention, the
following terms, unless otherwise indicated, shall be understood to have the following meanings:
The term ”drug”, ”active”, “bioactive material”, “active agent”, or “active pharmaceutical
ingredient” as used herein includes a pharmaceutically acceptable and therapeutically effective
compound, pharmaceutically acceptable salts, stereoisomers and mixtures of stereoisomers,
solvates (including hydrates), polymorphs, or prodrugs thereof. Unless otherwise indicated,
when referring to a drug in the descriptions of the various embodiments of the invention, the
reference encompasses the base drug, pharmaceutically acceptable salts, stereoisomers and
mixtures of stereoisomers, solvates (including hydrates), polymorphs, or prodrugs thereof.
The term “salts” refers to the product formed by the reaction of a suitable inorganic or
organic acid with the “free base” form of the drug. Suitable acids include those having sufficient
acidity to form a stable salt, for example acids with low toxicity, such as the salts approved for
use in humans or animals. Non-limiting examples of acids that may be used to form salts of a
vaginally active drug such as metronidazole or tenofovir include inorganic acids, e.g., HF, HCl,
HBr, HI, H2SO4, H3PO4; non-limiting examples of organic acids include organic sulfonic acids,
such as C6-16 aryl sulfonic acids, C6-16 heteroaryl sulfonic acids, or C1-16 alkyl sulfonic acids –
e.g., phenyl, -naphthyl, -naphthyl, (S)-camphor, methyl, ethyl, n-propyl, i-propyl, n-butyl,
sec-butyl, i-butyl, t-butyl, pentyl and hexyl sulfonic acids; non-limiting examples of organic
acids includes carboxylic acids such as C1-16 alkyl, C6-16 aryl carboxylic acids, and C4-16
heteroaryl carboxylic acids, e.g., acetic, glycolic, lactic, pyruvic, malonic, glutaric, tartaric, citric,
fumaric, succinic, malic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic,
cinnamic, salicylic and 2-phenoxybenzoic acids; non-limiting examples of organic acids include
amino acids, e.g., the naturally-occurring amino acids, lysine, arginine, glutamic acid, glycine,
serine, threonine, alanine, isoleucine, leucine, etc. Other suitable salts can be found in, e.g., S. M.
Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19. In most embodiments, “salts” refers to salts that
are biologically compatible or pharmaceutically acceptable or non-toxic, particularly for
206449NZ_spec_20160212_PLH
mammalian cells. The salts of drugs useful in the invention may be crystalline or amorphous, or
mixtures of different crystalline forms or mixtures of crystalline and amorphous forms.
The term "prodrug" means a form of a compound suitable for administration to a patient
without undue toxicity, irritation, allergic response, and the like, and effective for an intended
use, including ketal, ester, and zwitterionic forms. A prodrug is transformed in vivo, for example
by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs
as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche,
ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon
Press, 1987.
The terms “rapid dissolve tablet”, “rapid disintegrating tablet”, or “RDT” refer to a tablet
that disintegrates rapidly, such as in about 8 min, about 6 min, about 4 min, or about 2 min, in
the vaginal cavity of a patient after administration/insertion into the vaginal cavity. The rate of
disintegration can vary, but is slower than the rate of disintegration of orally disintegrating
tablets, or faster than the rate of disintegration of conventional or bioadhesive vaginal tablets,
when tested as described herein (e.g., the USP <701> disintegration time test method).
The term “substantially disintegrates” refers to a level of disintegration amounting to
disintegration of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at
least about 90%, or about 100% disintegration. The term "disintegration" is distinguished from
the term "dissolution" in that "disintegration" refers to the breaking up of or loss of structural
cohesion of the constituent particles comprising a tablet, whereas "dissolution" refers to the
solubilization of a solid in a liquid (e.g., the solubilization of a drug in solvents or gastric fluids).
The term “water-soluble polymer” refers to a polymer that is soluble (i.e., a significant
amount dissolves) in aqueous media, independent of pH.
The term “bioadhesive material” refers to a polymer that improves adherence of the
pharmaceutical composition containing a bioadhesive material to mucosa or similar biological
surface compared to the adherence of the pharmaceutical composition without the bioadhesive
material. Non-limiting examples of bioadhesive materials include bioadhesive polymers such as
206449NZ_spec_20160212_PLH
hydroxypropylcellulose.
The term “patient compliance” refers to non-adherence to dosing regimens by patients
who are prescribed to follow a certain dosing regimen of a particular medication in need. Non-
compliance or adherence to a dosing regimen is a major medical problem in the world costing
billions of dollars and affecting lifestyles of millions of people.
The term “about” used herein in reference to a numerical quantity includes the noted
numerical quantity, as well as values near the numerical quantity. For example, “about 60
second” includes 60 seconds, exactly, as well as values close to 60 seconds (e.g., 50 seconds, 55
seconds, 59 seconds, 61 seconds, 65 seconds, 70 seconds, etc.).
The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated
to refer to alternatives only or the alternatives are mutually exclusive. It is specifically
contemplated that any listing of items using the term “or” means that any of those listed items may
also be specifically excluded from the related embodiment.
Following long-standing patent law, the words “a” and “an,” when used in conjunction
with the word “comprising” in the claims or specification, denotes one or more, unless
specifically noted.
Unless stated otherwise, the amount of the various pharmaceutically acceptable actives or
excipients incorporated into various pharmaceutical compositions in accordance with certain
embodiments of the present invention is expressed as the percentage weight of the composition
as granulate or RDT. Thus, a 10% of an active in the RDT composition refers to the presence or
content of the active in the RDT by 10 weight%.
In some embodiments, the present invention is directed to a pharmaceutical composition
comprising a drug selected from the group consisting of antifungal agents; antibacterial agents;
antimicrobial agents; antiviral agents; anti-infectives; spermicides; hormones; antibiotics;
antiviral agents; analgesics; antitrichomonial agents; antiprotozoan agents; antimycoplasm
agents; antiretroviral agents; nucleoside analogues; reverse transcriptase inhibitors; protease
inhibitors; contraceptive agents; anorexics and appetite suppressants; steroids; anthelmintics;
206449NZ_spec_20160212_PLH
anesthetics; antiarthritics; antiasthma agents; anticonvulsants; antidepressants; antidiabetic
agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations;
antimotion sickness agents; antinauseants; antineoplastics; antiparkinsonism agents; antipruritics;
antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine
derivatives; cardiovascular preparations; calcium channel blockers; beta blockers;
antiarrhythmics; antihypertensives; diuretics; vasodilators that are general, coronary, peripheral
or cerebral; erectile dysfunction agents; central nervous system stimulants; cough and cold
preparations; decongestants; hormones; hypnotics; immunosuppressives; muscle relaxants;
parasympatholytics; tranquilizers; antioxidants; vitamins, minerals; and herbal extracts or
preparations; parasympathomimetics; psychostimulants; sedatives; orally active drugs exhibiting
significant first-pass effects; or combinations thereof, proteins/peptides, reverse transcriptase
inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
integrase inhibitors, growth enhancing hormones and luteinizing-hormone-releasing hormone
(LHRH), and the like, or a pharmaceutically acceptable salt, solvate, or ester thereof, suitable for
therapy by vaginal administration via topical action or systemic absorption.
Reverse transcriptase inhibitors RTIs are a class of antiretroviral drug used to treat HIV
infection, tumors, and cancer. RTIs inhibit the activity of reverse transcriptase, a viral DNA
polymerase enzyme that retroviruses need to reproduce. The mode of action of NRTIs is
essentially the same; they are analogues of naturally occurring deoxynucleotides needed to
synthesize viral DNA. NNRTIs are compounds that are specifically inhibitory to HIV-1
replication and target HIV-1 reverse transcriptase and have, in addition to the NRTIs and
protease inhibitors, gained a definitive place in the treatment of HIV-1 infections. PIs are a class
of drugs used to treat or prevent infection by viruses, including HIV and Hepatitis C. Integrase
inhibitors (e.g., elvitegravir and MK-2048) are a class of antiretroviral drugs designed to block
the action of integrase, a viral enzyme that inserts the viral genome into the DNA of a host cell.
Accordingly, in some embodiments, the present invention is directed to a pharmaceutical
composition comprising one or more drugs selected from the group of antiretroviral agents
206449NZ_spec_20160212_PLH
consisting of NRTIs (e.g., apricitabine , entecavir, emtricitabine, tenofovir, abacavir, adefovir,
their salts and mixtures thereof), NNRTIs (e.g., nevirapine, delavirdine, efavirenz, rilpivirine,
UC-781, MKC-442, quinoxaline HBY 097, DMP 266, their salts and mixtures thereof), protease
inhibitors (e.g., indinavir, amprenavir, darunavir, lotinavir, nelfinavir, ritonavir, sequinavir,
atazanavir, tipranavir, their salts and mixtures thereof), and integrase inhibitors (e.g., elvitegravir,
MK-2048, their salts and mixtures thereof) for the prevention of initial HIV infection, in addition
to treating individuals with HIV/AIDS to contain or eliminate the growth or severity of AIDS.
Various commercial vaginal creams, ointments, gels, inserts/rings, and tablets are currently
available. For example, Dahl discloses in EP 1773296 the preparation of a pharmaceutical
vaginal gel comprising tenofovir. This dosage form may not benefit individuals with AIDS or
those who want to avoid the risk of HIV transmission or infections during sexual activity, as the
gel/applicator−like other similar gel formulations−may suffer from limitations such as leakage,
messiness, and low residence time. However, it is very desirable to provide improved
compositions and methods which reduce the risk of HIV transmission or infections during sexual
activity.
In certain embodiments, the present invention is directed to a pharmaceutical
composition in the form of rapid dissolve microgranules or tablets comprising at least one drug
suitable for vaginal administration selected from the group consisting of a bisphosphonate (e.g.,
alendronate, clodronate, etidronate, pamidronate, tiludronate, ibandronate, neridronate,
risedronate, zoledronic acid, incadronate, minodronate, and olpadronate); an anti-migraine drug,
such as one selected from the group consisting of ergotamine, dihydroergotamine, ergostine,
butalbital, phenobarbital, acetaminophen, diclofenac sodium, ketoprofen, ketorolac, ibuprofen,
piroxicam, naproxen, acetylsalicylic acid, flurbiprofen, tolfenamic acid, butorphanol,
meperidine, methadone, sumatriptan, naratriptan, razatriptan, zolmitriptan, almotriptan,
eletriptan, dexamethasone, hydrocortisone, isometheptene, chlorpromazine, diazepam,
droperidol, valproic acid, gabapentin, topiramate and divalproex sodium; an anti-nausea drug,
such as one selected from the group consisting of metoclopramide, prochlorperazine,
domperidone, ondansetron, tropisetron, dolasetron, nabilone, dronabinol, levonantradol,
206449NZ_spec_20160212_PLH
aprepitant, cyclizine, promethazine, sildenafil, oxytocin, oxytocin, oxybutynin, bromocriptine,
rifamycin, azithromycin; steroids used in hormone replacement therapy or for contraception;
calcitonin; LHRH and analogues; insulin; and human growth hormones, and combinations
thereof. Vaginally administratable dosage forms may be employed, such as those including
suppositories that contain poorly soluble/bioavailable drugs and effervescent agents as
penetration enhancers, and one or more mucoadhesive polymers (e.g., carbomers, chitosan,
hydroxyethylcellulose), surfactants (e.g., glyceryl palmitostearate), or lipids (e.g., glyceryl
palmitostearate, phospholipid).
In certain embodiments, the present invention is directed to a pharmaceutical composition
in the form of rapid dissolve microgranules comprising at least one drug suitable for vaginal
administration, at least one sugar alcohol such as mannitol or a saccharide such as lactose, and at
least one polymeric binder such as low-substituted hydroxyethylcellulose. Such compositions
may be used, for example, for therapy via topical action or systemic absorption upon insertion of
the medicinal composition into the vaginal cavity of a patient/subject in need thereof.
In certain embodiments of the present invention, the pharmaceutical composition in the
form of rapid dissolve microgranules further comprises a disintegrant such as crospovidone.
This disintegrant may facilitate rapid disintegration of rapid dissolve microgranules to form a
viscous drug-containing suspension in the vaginal cavity of a patient/subject in need thereof.
In certain other embodiments of the present invention, the pharmaceutical composition in
the form of rapid dissolve microgranules further comprises at least one bioadhesive polymer,
such as low-substituted hydroxyethylcellulose, This bioadhesive polymer may be provided at a
desired concentration, which may, upon forming a viscous drug-containing suspension in the
vaginal cavity of a patient/subject, coat the vaginal mucosa, thereby improving its bioadherence
and therapeutic efficacy via longer retention for topical action or systemic absorption.
Examples of sugar alcohols/saccharides include, but are not limited to, mannitol, sorbitol,
xylitol, arabitol, erythritol, glycerol, hydrogenated starch hydrolysate, isomalt, lactitol, lactose,
maltitol, sucrose, maltose, and combinations thereof.
206449NZ_spec_20160212_PLH
Examples of suitable binders include, but are not limited to, polyvinylpyrrolidone (PVP),
polyethylene oxide, hydroxypropyl methylcellulose or hypromellose (e.g., Methocel E5 or E15,
or Pharmacoat™ 603), hydroxypropylcellulose (e.g., Klucel LF), low-substituted
hydroxyethylcellulose, and polysaccharides. The binder can be present in an amount ranging
from, e.g., about 0.5 - 3 weight % based on the rapid dissolve microgranules.
Examples of disintegrants include, but are not limited to crospovidone, sodium starch
glycolate, starch, crosslinked sodium carboxymethylcellulose, low-substituted
hydroxypropylcellulose, gums (e.g., gellan gum), and combinations thereof. The disintegrant
can be present in the pharmaceutical composition in the form of rapid dissolve microgranules,
for example, from about 1% to about 10%, from about 3% to about 7%, to about 5%, inclusive of
all ranges and subranges there between.
Non-limiting examples of suitable bioadhesive polymers include, but are not limited to,
hydroxypropylcellulose, hypromellose, low-substituted hydroxyethylcellulose,
hydroxyethylethylcellulose, polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone-
polyvinyl acetate copolymer (e.g., Kollidon VA 64 from BASF), polyvinyl alcohol,
polyethylene oxide, carbomers (CARBOPOL 974P, 941, 940, 934, G70), poly(lactic co-
glycolic acid), polyamide, carrageenan, chitosan, and various cellulosic gums (e.g., xanthan
gum). The bioadhesive polymer can be present in the pharmaceutical composition in the form of
rapid dissolve microgranules, from, for example, about 3% to about 10%, from about 4% to
about 8%, to about 5%, inclusive of all ranges and subranges there between.
Non-limiting examples of suitable surfactants that may be employed include DL-alpha
tocopherol, surfactants (e.g., CAPTEX 200, Tween 20, Tween 80, Vitamin E TPGS, Capryol 90,
CREMOPHOR EL, CARBITOL, PEG 400, lecithin, Brij 92, LABRASOL, triacetin, sodium
lauryl sulfate, ethylene glycol monostearate, polysorbates and poloxamers , GELUCIRE ,
® ® ®
LABRAFIL , LABRASOL , IMWITOR , sodium lauryl salicylate, sodium dodecyl sulfate),
and mixtures thereof.
Non-limiting examples of suitable lipids that may be employed include lecithins;
hydrogenated lecithins; lysolecithin, hydrogenated lysolecithins; lysophospholipids and
206449NZ_spec_20160212_PLH
derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty
acids; sodium docusate; stearyl alcohol, glyceryl palmitostearate (PRECIROL ATO 5);
mixtures of mono-, di-, and tri-esters of glycerol (GELUCIRE ), mono- and di-esters of PEG,
free PEG, and mixtures thereof.
In certain embodiments of the present invention, a pharmaceutical composition in the
form of a rapid dissolve tablet further comprises rapidly dispersing microgranules comprising a
saccharide or a sugar alcohol in combination with a disintegrant, produced in accordance with
the specifications co-pending U.S. Patent Application Ser. No. 10/827,106 (published as US
2005/0232988). Yet in certain other embodiments of the present invention, the rapid dissolve
tablet composition can further comprise rapidly dispersing microgranules comprising a sugar
alcohol such as mannitol, a super disintegrant such as low-substituted hydroxypropylcellulose,
and an additive with multi-functionality of a binder and disintegrant such as starch, modified
starch and hydroxypropylcellulose.
Suitable disintegrants include, but are not limited to, crospovidone, sodium starch
glycolate, starch, crosslinked sodium carboxymethylcellulose, low-substituted
hydroxypropylcellulose, gums (e.g., gellan gum), and combinations thereof. Exemplary
saccharides or sugar alcohols may be selected from the group consisting of arabitol, erythritol,
glycerol, hydrogenated starch hydrolysate, isomalt, lactitol, lactose, maltitol, mannitol, sorbitol,
xylitol, sucrose, maltose, and combinations thereof. The saccharide or sugar alcohol may also be
supplemented or replaced with artificial sweeteners such as sucralose. The ratio of the
disintegrant to the saccharide or sugar alcohol in the rapidly dispersing microgranules typically
ranges from about 1:99 to about 10:90, or from about 5:95 to about 10:90 on a weight basis and
inclusive of all ranges and subranges there between. In some embodiments, the disintegrant or
the saccharide or sugar alcohol, or both, are present in the form of particles having an average
particle size of about 30 µm or less in accordance with the specifications in co-pending U.S.
Patent Application Ser. No. 10/827,106 (published as US 2005/0232988) and where the
composition has a multifunctional additive the saccharide or sugar alcohol, are present in the
form of particles having an average particle size of about 60 µm or less. The multifunctional
206449NZ_spec_20160212_PLH
additive may be present in the rapidly dispersing microgranule composition at 1-2.5% by weight,
for example. The ratio of the drug-containing granules to the rapidly disintegrating granules can
range from about 5:1 to about 1:5, from about 3:1 to about 1:3, or from about 2:1to about 1:2, or
about 1:1, inclusive of all ranges and subranges there between.
The in vitro dissolution testing of pharmaceutical compositions of the present invention is
performed using United States Pharmacopeia I (paddles at 100 rpm) or II (paddles at 50 rpm) and
an appropriate dissolution media (900 mL) (HPLC method) depending on the drug(s).
Disintegration of the RDTs of the invention is tested according to the USP <701>
Disintegration Test. Alternately, disintegration time of pharmaceutical compositions prepared as
RDT tablets may be determined using a vaginal fluid stimulant prepared in accordance with the
disclosure by Owen and Katz (Owen and Katz, 1999. Contraception. 59, 91-95). In view of the
small volume of fluid available in the vaginal cavity, dissolution testing may be performed by
dropping RDTs in test tubes containing a small amount of buffer (e.g., 3.5 mL) of ammonium
acetate buffer at a pH of about 6, and at appropriate time points centrifuging at 4000 rpm for 2
min, and testing samples filtered through 0.45 µm PTFF filters by HPLC.
In a particular embodiment, an RDT of the invention comprises a therapeutically
effective amount of tenofovir, or pharmaceutically acceptable salts thereof, alone or in
combination with emitricitabine at a ratio of from about 2:1 to about 1:10, from about 1:1 to
about 1:8, or from about 1:2 to about 1:6, or about 1:5. After insertion into the vagina, the RDT
substantially disintegrates in the vaginal cavity of a patient, forming a viscous, easy-to-spread
suspension that spreads/coats the vaginal mucosa to provide efficacy via topical action or
systemic absorption. In addition to the rapidly dispersing microgranules, an RDT of the
invention optionally includes a pharmaceutically acceptable bioadhesive polymer, such as one
selected from the group consisting of low-substituted hydroxyethylcellulose,
hydroxypropylcellulose, hypromellose, polycarboxylic acids, polyvinylpyrrolidone,
vinylpyrrolidone-polyvinyl acetate copolymer (e.g., Kollidon VA 64 from BASF),
SOLUPLUS , poly(ethylene glycol 6000 - vinylcaprolactam - vinyl acetate) (13:57:30)
copolymer from BASF), polyvinyl alcohol, polyethylene oxide, poly(lactic co-glycolic acid),
206449NZ_spec_20160212_PLH
polyamide, alginic acid salts, carrageenan, chitosan, and various cellulosic gums (e.g., xanthan
gum).
In some embodiments, an RDT weighs not less than about 50 mg; for example, 100 mg
or more; 200 mg or more; 300 mg or more; or 500 mg or more. In some other embodiments, the
RDT weighs not more than about 2000 mg; for example, 1600 mg or less; 1400 mg or less; 1200
mg or less; 1000 mg or less; 800 mg or less; or 500 mg or less. In another embodiment, the RDT
weighs not more than about 800 mg. In another embodiment, the RDT weighs not more than
about 600 mg. In another embodiment, the RDT weights not more than 500 mg. The dosage
forms of the invention can, for example, comprise two or more populations of antibiotic drug-
containing particles, such as including at least one population of metronidazole particles as
described herein. A dosage form can, for example, comprise a population of tenofovir, a
nucleoside reverse transcriptase inhibitor, rapid dissolve particles as described herein, and in
addition, a population of emitricitabine particles, for the prevention of AIDS.
In one embodiment, a treatment as described herein targets two specific viral enzymes:
reverse transcriptase (e.g., using NRTIs or NNRTIs) and protease (e.g., using protease
inhibitors).
A pharmaceutical composition of the present invention in the form of a rapid dissolve
tablet for vaginal administration may comprise a therapeutically effective amount of propranolol,
a non-selective beta blocker undergoing extensive first-pass (hepatic) metabolism upon oral
administration, or pharmaceutically acceptable salt or a mixture thereof.
A pharmaceutical composition of the present invention in the form of a rapid dissolve
tablet for vaginal administration may comprise a therapeutically effective amount of
metronidazole, and optionally an antibiotic selected from the group consisting of clarithromycin,
sulfonamides, erythromycin, azithromycin, doxycycline, quinolones, cefoxitin, ceftriaxone
cifrofloxacin, doxyclycline, vancomycin, clindamycin, rifaximin, and metronidazole.
A pharmaceutical composition of the present invention in the form of a rapid dissolve
tablet for vaginal administration may comprise a therapeutically effective amount of
206449NZ_spec_20160212_PLH
clotrimazole, and optionally an antifungal agent selected from the group consisting of nystatin,
ketoconazole, itraconazole, and clotrimazole.
In certain embodiments, the present invention is directed to a method of preparing first a
rapid dissolve microgranule composition comprising at least one sugar alcohol, saccharide, or
mixture thereof, a polymeric binder, optionally a super disintegrant or bioadhesive polymer, and
a therapeutically effective amount of at least one drug selected from the group consisting of
antifungal agents, antibacterial agents, antimicrobial agents, antiviral agents, spermicides,
hormone agents, antitrichomonial agents, antiprotozoan agents, antimycoplasm agents,
antiretroviral agents, nucleoside analogues, reverse transcriptase inhibitors, protease inhibitors,
contraceptive agents, proteins, peptides, steroids, growth enhancing agents, and the like, or a
pharmaceutically acceptable salt, solvate, or ester thereof, suitable for administration by the
vaginal route, next blending drug-containing rapid dissolve microgranules with rapidly
dispersing microgranules prepared in accordance with the specifications in co-pending U.S.
Patent Application Ser. No. 10/827,106 (published as US 2005/0232988, and compressing into
rapid dissolve tablets (RDTs) containing a therapeutically effective dose. The RDT rapidly
disintegrates in the vaginal cavity of a patient/subject forming a viscous drug-containing
suspension which is expected to spread rapidly and widely coating the vaginal mucosa for the
treatment of the disease via topical action or systemic absorption.
In certain other embodiments, the present invention is directed to a method of preparing
first a rapid dissolve microgranule composition comprising at least one sugar alcohol, saccharide,
or mixture thereof, a polymeric binder, optionally a super disintegrant or bioadhesive polymer,
and a therapeutically effective amount of at least one drug selected from the group of
antiretroviral agents consisting of NRTIs (e.g., apricitabine , entecavir, emtricitabine, tenofovir,
abacavir, adefovir, their salts and mixtures thereof), NNRTIs (e.g., nevirapine, delavirdine,
efavirenz, UC-781, MKC-442, quinoxaline HBY 097, DMP 266, their salts and mixtures
thereof), protease inhibitors (e.g., indinavir, amprenavir, darunavir, lotinavir, nelfinavir,
ritonavir, sequinavir, atazanavir, tipranavir, their salts and mixtures thereof), and integrase
inhibitors (e.g., elvitegravir, MK-2048, their salts and mixtures thereof), next blending drug-
206449NZ_spec_20160212_PLH
containing rapid dissolve microgranules with rapidly dispersing microgranules, and compressing
into RDT tablets containing a therapeutically effective dose for the prevention of initial infection
of, in addition to treating individuals with, HIV/AIDS, such as to contain or eliminate the growth
or severity of AIDS. Various commercial vaginal creams, ointments, gels, inserts/rings, and
tablets are currently available. For example, Dahl discloses in EP 1773296 the preparation of a
pharmaceutical vaginal gel comprising tenofovir. This dosage form may not benefit individuals
with AIDS or those who want to avoid the risk of HIV transmission or infections during sexual
activity, as the gel/applicator−like other similar gel formulations−may suffer from limitations
such as leakage, messiness, and low residence time. However, it is very desirable to provide
improved compositions and methods which reduce the risk of HIV transmission and/or infections
during sexual activity.
In certain other embodiments, the present invention is related to a method of preparing a
rapid dissolve tablet composition comprising at least one sugar alcohol such as mannitol, a
polymeric binder such as low-substituted hydroxypropylcellulose, optionally a disintegrant such
as crospovidone, and one NRTI alone, such as tenofovir or emtricitabine, or one or more NRTIs,
such as tenofovir in combination with emtricitabine or dapivirene, and then form rapid dissolve
tablets by compressing a formulation comprising said rapid dissolve microgranules, rapidly
dispersing microgranules, microcrystalline cellulose, a super disintegrant such as crospovidone,
and a lubricant such as sodium stearyl fumarate on a rotary tablet press.
In another embodiment, a method of preparing a rapid dissolve microgranules comprises
granulating a composition as described herein, further comprising a bioadhesive polymer (e.g.,
low-substituted hydroxyethylcellulose) for incorporation into an RDT, which improves
bioadherence of the viscous drug suspension to the surface of the vaginal mucosa upon insertion
of the RDT into the vaginal cavity.
The granulation method is not limited; a fluid bed or high shear granulation method using
a solution of a polymeric binder dissolved in purified water, ethanol, isopropanol, acetone, or a
mixture thereof, is an embodiment of the present invention. In accordance with the present
invention, for example, granulation may be performed by spraying a solution comprising a
206449NZ_spec_20160212_PLH
polymeric binder and a drug dissolved or homogeneously suspended therein onto the powder
mixture comprising at least one sugar alcohol and optionally a disintegrant or a bioadhesive
polymer such as low-substituted hydroxyethylcellulose in a top spray fluid bed granulator such
as Glatt GPCG 3, GPCG 5, GPCG 120, or Fluid Air FA0300, and drying the granulation in the
same fluid-bed dryer. The granulation may also be performed using a high shear granulator, such
as GMX 25 (batch size: 4-7 kg), GMX 65, or GMX 600 (batch size: 140-160 kg) from Vector
and drying in the Glatt. The dried granulation thus produced may be sieved by passing through
appropriate sieves to collect rapid dissolve drug-containing microgranules with a desired particle
size distribution by discarding fines and optionally milling/resieving oversized granules.
The drug-containing microparticles granulated with one or more bioadhesive polymers to
improve bioadherence characteristics to the vaginal mucosa may have a median particle size in
the range of about 100-400 μm. In some embodiments, not less than 90% of the microparticles
are smaller than 600 μm for their incorporation into a rapid dissolve tablet.
In yet another embodiment, the invention may be directed to a method of preparing a
rapid dissolve tablet by blending rapid dissolve drug-containing microgranules and rapidly
dispersing microgranules prepared as described herein and compressing on a rotary tablet press
into rapid dissolve tablets for administration into vaginal cavity of a patient in need of such a
medication for therapeutic efficacy via topical action or systemic absorption.
A rapid dissolve tablet of the present invention can be produced by an internal lubrication
method, for example, wherein the compression mix is further blended with a lubricant prior to
compression. Alternately, a rapid dissolve tablet can be produced by an external lubrication
method wherein a lubricant is not included in the tablet formulation, but is externally applied
onto the material contacting surfaces of punches and dies of a rotary tablet press. Lubricants such
as magnesium stearate, calcium stearate, zinc stearate, stearic aid, sodium stearyl fumarate,
glyceryl behenate, and the like may be used for lubricating the granules, or may be externally
applied onto material contacting die and punch surfaces of a rotary tablet press used to compress
tablets.
Another embodiment according to the invention is directed to a method of treating a
206449NZ_spec_20160212_PLH
patient or subject comprising administering a composition of the invention as a rapid dissolve
tablet containing a therapeutically effective amount of one or more drugs selected from the group
consisting of antifungal agents, antibacterial agents, antimicrobial agents, antiviral agents,
spermicides, hormones, antitrichomonial agents, antiprotozoan agents, antimycoplasm agents,
antiretroviral agents, nucleoside analogues, reverse transcriptase inhibitors, protease inhibitors,
contraceptive agents, steroids, orally active drugs exhibiting significant first-pass effects,
proteins/peptides including growth enhancing hormones and luteinizing-hormone-releasing
hormone (LHRH), by insertion into the vaginal cavity of a patient in need thereof.
EXAMPLES
The invention is described in greater detail in the sections below. Many of the examples
provided below to illustrate the invention involve tenofovir alone, or in combination with
emtricitabine. It should be understood that the examples and embodiments described herein are
for illustrative purposes only and that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included within the spirit and purview of this
application.
Example 1
A: RD Microgranules comprising tenofivir, crospovidone, and Klucel:
Sodium bicarbonate (54 g) is slowly added to purified water (2800 g) in a stainless steel
container while continuously stirring to dissolve. The pH of the bicarbonate solution is adjusted
to about 6.0 if needed by adding hydrochloric acid. Hydroxypropylcellulose (Klucel LF; 125 g)
is slowly added while stirring to dissolve; then tenofovir (180 g) is added to dissolve. Preheated
Glatt GPCG 3 equipped with top spray insert, granulation air distribution bottom plate, 200 mesh
product retention screen, and 1.0 mm spray nozzle is charged with mannitol with an average
particle size of less than 30 µm (781 g) and crospovidone (60 g), both deagglomerated by
passing through Comil. The rapid dissolve microgranule composition is granulated while
fluidizing the charge continuously and maintaining the process parameters at the following
conditions: product temperature - 34±1°C; fluidization air flow – 10 CFM; spray rate – 10-16
206449NZ_spec_20160212_PLH
mL/min. Upon completion of spraying, the RD microgranules are dried for a loss on drying to
about 1% by weight.
B: RD Microgranules comprising tenofivir, crospovidone, and L-HEC:
Sodium bicarbonate (54 g) is slowly added to purified water (2500 g) in a stainless steel
container while continuously stirring to dissolve. The pH of the bicarbonate solution is adjusted
to about 6.0 if needed by adding hydrochloric acid. Low-substituted hydroxyethylcellulose (L-
HEC; 20 g) is slowly added while stirring to dissolve; then tenofovir (180 g) is added to dissolve.
Preheated Glatt GPCG 3 is charged with deagglomerated mannitol (781 g) and crospovidone (60
g) and fluidized. The RD microgranules are prepared by spraying the solution as disclosed in
step Ex.1A above.
C: RD Microgranules comprising tenofivir, crospovidone, and HPMC:
Sodium bicarbonate (39.1 g) is slowly added to purified water (2500 g) in a stainless steel
container while continuously stirring to dissolve. The pH of the bicarbonate solution is adjusted
to about 6. if needed by adding hydrochloric acid. Hypromellose (HPMC; 18.1g) is slowly added
while stirring to dissolve; then tenofovir (183.2 g) is added to dissolve. Preheated Glatt GPCG 3
is charged with deagglomerated mannitol (637.4 g) and crospovidone (43.1 g) and fluidized. The
RD microgranules are prepared by spraying the solution as disclosed in step Ex.1A above
D. Rapidly Dispersing Microgranules:
Rapidly dispersing microgranules are prepared following the procedure disclosed in co-
pending US Patent Application Publication No. U.S. 2003/0215500. Specifically, D-mannitol
(152 kg) with an average particle size of approximately 20 µm or less (Pearlitol 25 from
Roquette, France) is blended with 8 kg of cross-linked povidone (Crospovidone XL-10 from
ISP) in a high shear granulator (GMX 600 from Vector), granulated with purified water
(approximately 32 kg), wet-milled using a Comil from Quadro, and finally tray-dried to provide
microgranules having an LOD (loss on drying) of less than about 0.8%. The dried granules are
sieved, and oversize material is again milled to produce rapidly dispersing microgranules with an
average particle size in the range of approximately 175-300 µm.
206449NZ_spec_20160212_PLH
E: Tenofivir RDTs (Crospovidone):
RDT tablet formulations containing tenofovir (TFV) RD microgranules of Ex. 1A, Ex.
1B, and Ex. 1C are compressed (see Table 1 for compositions) on a Hata tablet press equipped
with partial tooling at the turret speed of 15 RPM. Half of the rapidly dispersing microgranules is
charged into a 0.25 cu-ft V blender, followed by crospovidone, microcrystalline cellulose
(Avicel PH101), TFV RD granules, and the remaining half of the rapidly dispersing
microgranules and blended for 10 min. Sodium stearyl fumarate (Pruv) passed through 35 mesh
screen is added to the compression mix and blended 2 min. The Hata tablet press is set up in the
manual mode for a fill weight of 150 mg and hardness of 10-50 N. Once the set up is complete,
the tablet press is run at a compression force of 3, 4, and 5 kN in the ‘Auto’ mode. Tablets are
collected at steady state for each compression force for testing of weight, thickness, hardness,
and friability. The average values tested for each tablet batches are presented in Table 1. The
disintegration times tested in accordance with USP method <701> for DT are 60-90 sec, 30-60
sec, and 30-60 sec, respectively for tenofovir RDT tablet batches of Formula Ex. 1AD (TFV
RDG: Ex. 1A), Formula Ex. 1BD (TFV RDG: Ex. 1B), and Formula Ex. 1CD (TFV RDG: Ex.
1C). RDTs of these formulations compressed at 4 kN are observed to disintegrate in 30-60 sec
when tested by the USP method <701> and not less than 80% dissolved at 30 min when tested
for dissolution in test tubes.
Table 1: Compositions of Tenofovir RDTs
Ingredients Formula Ex. 1AD Formula Ex. 1BD Formula Ex. 1CD
(TFV RDG: Ex. 1A) (RDG: Ex. 1B) (RDG: Ex. 1C)
mg/tablet g/batch mg/tablet g/batch mg/tablet g/batch
TFV RD 66.67 888.9 66.67 888.9 108.70 942.0
Microgranules
Rapidly Dispersing 58.58 781.1 58.58 781.1 16.55 143.5
Granules
206449NZ_spec_20160212_PLH
Crospovidone 7.5 100.0 7.5 100.0 7.5 65.0
Avicel PH101 15.0 200.0 15.0 200.0 15.0 120.0
Sodium stearyl 2.3 30.0 2.3 30.0 2.3 19.5
fumarate
Total 150.0 2000 150.0 2000 150.0 1300
Parameter Formula Ex. 1AD Formula Ex. 1BD Formula Ex. 1CD
Compression 3 kN 4 kN 5 kN 3 kN 4 kN 5 kN 3 kN 4 kN 5 kN
Force
Weight (mg) 152 154 149 153 153 151 149 148 154
Thickness, mm 3.94 3.73 3.52 3.89 3.69 3.51 3.82 3.67 3.58
Hardness, N 17 35 36 13 24 36 13 20 39
Friability 0.4% 0.11% 0.17% 0.51% 0.29% 0.26% 0.58% 0.23% 0.13%
Example 2
A: RD Microgranules Comprising Tenofivir:
Sodium bicarbonate (67.5 g) is slowly added to purified water (2010 g) in a stainless steel
container while continuously stirring to dissolve. The pH of the bicarbonate solution is
measured to be about 6.8. Hypromellose (Methocel; 62.5 g) is slowly added while stirring to
dissolve; then tenofovir (190 g) is added to dissolve. Preheated Glatt GPCG 3 is charged with
deagglomerated mannitol (890 g) and fluidized. The rapid dissolve microgranules are prepared
while spraying the charge and maintaining the process parameters at the following conditions:
product temperature - 34±1°C; fluidization air flow – 5 to 15 CFM; spray rate – 4-16 mL/min.
206449NZ_spec_20160212_PLH
Upon completion of spraying, the RD microgranules are dried for a loss on drying to about 1%
by weight.
B: RD Microgranules Comprising Tenofivir:
Sodium bicarbonate (57 g) is slowly added to a mixture of ethanol (540 g) and purified
water (1260 g) in a stainless steel container while continuously stirring to dissolve. The pH of
the bicarbonate solution is measured to be about 6.2. Next, tenofovir (200 g) is added to dissolve
followed by the addition of Low-substituted hydroxyethylcellulose (L-HEC; 20 g) to dissolve
while stirring. Preheated Glatt GPCG 3 is charged with deagglomerated mannitol (1023 g) and
fluidized. The RD microgranules are prepared by spraying the solution at the following
conditions: product temperature - 34±1°C; fluidization air flow – 4 CFM; spray rate – 8-12
mL/min. Upon completion of spraying, the RD microgranules are dried for a loss on drying to
about 1% by weight.
C: RD Microgranules Comprising Tenofivir:
Sodium bicarbonate (54 g) is slowly added to a mixture of ethanol (540 g) and purified
water (1260 g) in a stainless steel container while continuously stirring to dissolve. The pH of
the bicarbonate solution is measured to be about 6.15. Next, tenofovir (200 g) is added to
dissolve followed by the addition of Low-substituted hydroxyethylcellulose (L-HEC; 30 g) to
dissolve while stirring. Preheated Glatt GPCG 3 is charged with deagglomerated mannitol (1023
g) and fluidized. The RD microgranules are prepared by spraying the solution as disclosed in
step Ex.2B above. Upon completion of spraying, the loss on drying of RD microgranules is about
1.5% by weight.
D. Tenofivir RDTs:
RDT tablet formulations (Formula Ex. 2BD and Formula Ex. 2CD) containing tenofovir
(TFV) RD microgranules of Ex. 2B and Ex. 2C are compressed (see Table 2 for compositions)
on a Hata tablet press equipped with partial tooling at the compression force of 4 kN and turret
speed of 15 RPM. Samples are collected at the start, mid, and end of the run for testing for in-
206449NZ_spec_20160212_PLH
process tablet properties. The results are presented in Table 2. In case of Formula Ex. 2AD,
tablets are compressed using a Carver press.
Table 2: Compositions of Tenofovir RDTs
Ingredients Formula Ex. 2AD* Formula Ex. 2BD Formula Ex. 2CD
(TFV RDG: Ex. 2A) (TFV RDG: Ex. 2B) (TFV RDG: Ex. 2C)
mg/tablet g/batch mg/tablet g/batch mg/tablet g/batch
TFV RD Microgranules 63.69 21.23 62.89 838.6 61.35 818.0
Rapidly Dispersing 61.56 20.52 62.36 831.4 63.90 852.0
Granules
Crospovidone 7.5 2.5 7.5 100.0 7.5 100.0
Avicel PH101 15.0 5.0 15.0 200.0 15.0 200.0
Sodium stearyl fumarate 2.3 0.75 2.3 30.0 2.3 30.0
Total 150.0 50.0 150.0 2000 150.0 2000
Parameter Formula Ex. 2BD Formula Ex. 2CD
Compression Force (4 kN) Start Mid End Start Mid End
Weight (mg) 151 150 149 149 151 150
Thickness, mm 3.53 3.54 3.54 3.52 3.53 3.52
Hardness, N 39 34 29 38 32 28
Friability 0.05% 0.11% 0.13% 0.16% 0.15% 0.20%
206449NZ_spec_20160212_PLH
* — Tablets compressed using a Carver press.
E: Single and multi-dose PK study of tenofovir RDT vaginally administered in rabbits:
The objective of this study was to evaluate the pharmacokinetics of tenofovir after a
single dose or seven daily doses when administered in rapid dissolve tablet form in female
rabbits with a minimum body weight of 2.5 kg (n=6 in each group; blood sampled at 0, 0.5, 1, 2,
4, 8, and 24 hrs post dosing day 1 or 7 in group 1 & 3 and at 0, 0.5, 1.0, 1.5, and 2 hrs post
dosing day 1 or 7 in group 2 & 4). Prior to test article administration, acepromazine maleate (0.3-
0.5 mg/kg or to effect) was administered via subcutaneous administration to mildly sedate the
animal. Once sedated, a single tablet was inserted into the abdominal vagina of each animal
(approximately 8 cm) with an 18 catheter. No lubrication was used as this may affect tablet
absorption. A detailed clinical examination of each animal was performed daily during the study.
Observations included, but was not limited to, evaluation of the skin, fur, eyes, ears, nose, oral
cavity, thorax, abdomen, external genitalia, limbs and feet, respiratory and circulatory effects,
autonomic effects such as salivation, nervous system effects including tremors, convulsions,
reactivity to handling, and atypical behavior. Complete necropsy examinations were performed
for groups 1 and 3 on day 1 or 7 at 2 hrs or groups 2 and 4 at 24 hrs post dosing, under yellow
lighting using procedures approved by a veterinary pathologist on all animals found dead,
euthanized in extremis, or euthanized at each scheduled necropsy in accordance with current
SOP. Iliac lymph nodes were collected under yellow lighting for determination of total tenofovir
concentrations. Samples of Weck-Cel sponge were prepared by placing each Weck-Cel
sponge into the vagina in order to absorb secretions from the vagina for determination of total
tenofovir concentrations.
Figure 2 shows the mean tenofovir plasma concentration – time profiles following
insertion of a single tenofovir RDT (i.e., RDTs of Ex. 2CD) into the vaginal cavity of female
rabbits while Figure 3 shows the corresponding tenofovir concentrations following multi-dose (7
once-daily dosing) administration. Figure 4 shows the mean free and total tenofovir contents of
the abdominal and vaginal tissues at 2 and 24 hrs post dosing following insertion of a single
206449NZ_spec_20160212_PLH
tenofovir RDT into the vaginal cavity of female rabbits while Figure 5 shows the corresponding
fenofovir concentrations following multi-dose (7 once-daily dosing) administration. Figure 6
shows the mean predose and postdose tenofovir concentrations in Weck-Cel at 2 and 24 hrs
post dosing following insertion of a single tenofovir RDT into the vaginal cavity of female
rabbits while Figure 7 shows the corresponding predose and postdose tenofovir concentrations in
Weck-Cel following multi-dose (7 once-daily dosing) administration.
Further preclinical comparative PK studies in rabbits dosing 40 mg as rapid dissolve
tablets (four 10 mg tablets) versus 40 mg as 1% tenofovir gels (4 mL) suggest that the rapid
dissolve tablet form provides equivalent tissue concentrations as compared to the 1% TFV
gel. Unlike the gel dosage form which requires the use of a vaginal applicator and
accompanying packaging, the rapid dissolve tablet technology makes it very attractive in terms
of increased portability and potential reductions in manufacturing costs. Additionally, the
technology affords privacy and convenience of medication administration.
Example 3
A: RD Microgranules Comprising Tenofivir:
The high shear granulator GMX-25 is charged with tenofovir (TFV; 829.2 g), mannitol
(Pearlitol 25 with a mean particle size of less than 30 µm; 7829.2 g), hydroxyethylcellulose
(NITROSOL-HEC 250L; 91.6 g), and crospovidone (200 g). The contents of the product bowl
are well mixed with the impeller speed set at 150 RPM for 2 minutes. The powder mixture is
granulated by spraying purified water at a spray rate of about 100 g/min at the following
processing parameters: spray nozzle pore size – 0.085”; impeller setting: speed – 325 RPM, time
- 5.5 min; Chopper setting speed – High, time – 5.5 min. After 5 minute, stop spraying, allow
the granulation to continue to mix for another 30 sec before stopping the granulator and scrape
the bowl, chopper blade and impeller blades. The spraying is continued to spray about 630 g of
water and the contents of the product bowl are mixed for another 2 minutes before discharging
the contents of the product bowl. The product bowl of pre-heated Glatt GPCG 5 is charged with
the moist granulation which is dried for a loss on drying of less than 2% as determined using a
Computrac Moisture Analyzer at 85°C. The drying conditions in the Glatt are as follows: product
206449NZ_spec_20160212_PLH
support screen – 200 mesh; inlet air temperature – 42°C; inlet air volume – 40 cfm; Desiccant
Wheel – ON.
B: RD Microgranules Comprising Emtricitabine:
Emtricitabine (FTC, 682.9 g) is slowly added to a mixture of ethanol (3974 g) and
purified water (995 g) in a stainless steel container while continuously stirring to dissolve. Next,
low-substituted hydroxyethylcellulose (Natrosol HEC-250L; 80.1 g) is added to
disperse/dissolve while stirring. Preheated Glatt GPCG 3 is charged with deagglomerated
mannitol (2737 g) and fluidized. The RD microgranules are prepared by spraying the solution at
the following conditions: product support screen – 200 mesh; nozzle tip size – 1.2 mm;
atomization pressure – 2 bar; inlet air temperature - 72°C; product temperature –38±1°C;
fluidization air flow – 40cfm; spray rate – 40 mL/min; desiccant wheel – ON. Upon completion
of spraying, the FTC RD microgranules are dried at the inlet air temperature set at 42°C for a
loss on drying to about 1% by weight.
C. RDTs (40-mg TFV/40-mg FCT)
RDT tablet formulations containing TFV RD microgranules of Ex. 3A and FCT RD
microgranules of Ex. 3B alone, or their mixtures thereof are first blended with other
pharmaceutical excipients including the lubricant, sodium stearyl fumarate and are compressed
(see Table 3 for compositions) on a Beta tablet press equipped with partial tooling at a
compression force of 4 – 6 kN and turret speed of 15 RPM. Samples are collected at the start,
mid, and end of each run for testing for in-process tablet properties.
The Manesty Beta press equipped with eight (8) 12 mm round, lozenge tooling having no
embossing is set up to the following parameters for 40 mg TFV / 40 mg FCT RDTs:
Tablet weight: total(10) – 5.00 g; Nominal: 500 mg; Range: 460-540 mg
Fill weight setting: 8 mm (or 6 mm for TFV); Pre-compression setting: 6 mm
Main compression: 3.3 mm (or 2.85 mm for TFV) Force feeder setting: 3.
206449NZ_spec_20160212_PLH
The press was set to run at 25 rpm and after a few die table/turret rotations, 10 tablets are
collected before stopping the press. Ten tablets are collected for determining the weight of 10
tablets and are inspected for tablet’s appearance (picking, capping, etc). The tablet press is
adjusted, as necessary, in order to produce tablets that meet the specifications listed above for
weight, thickness and hardness, and results are recorded on the production batch record. If
required, the parameters are readjusted as necessary to produce tablets that meet the friability
specifications listed above
At the beginning, middle and end of the process run, thirty five (35) tablets are sampled
for in- process testing. Ten tablets are tested for weight, hardness and thickness, and 6.5 g
tablets are tested for friability. Results are recorded on the production batch records. The rest of
the samples are combined in a properly labeled container as part of the composite sample. Each
in process test point will utilize a separate container for analytical testing.
Using similar settings, rapidly disintegrating tablets of 40-mg TFV/20-mg FCT, 20-mg
TFV/40-mg FCT, 40-mg TFV or 40-mg FCT are compressed from their respective compression
mixes.
Table 3: Compositions of RDTs (40 mg TFV; 40 mg FCT; 40 mg TFV/40 mg FCT;
40 mg TFV/20 mg FCT; 20 mg TFV/40 mg FCT)
Ingredients Formula Ex. 3C Formula Ex. 3C Formula Ex. 3C
40 mg TFC / 40 mg 40 mg/20 20 mg/40 40 mg 40 mg
FCT mg mg FTV FCT
mg/tablet g/batch g/batch g/batch mg/tablet g/batch
TFV RD Microgranules 205.0 1148.0 1148.0 574.0 1148.0 -
FCT RD Microgranules 205.0 1148.0 574.0 1148.0 - 1148.0
206449NZ_spec_20160212_PLH
Rapidly Dispersing 17.5 98.0 672.0 672.0 1288.0 1176.0
Granules
Crospovidone 17.5 98.0 980.0 98.0 56.0 140.0
Avicel PH101 50.0 280.0 280.0 280.0 280.0 280.0
Sodium stearyl fumarate 5.0 28.0 28.0 28.0 28.0 56.0
Total 500.0 2800 2800.0 2800 2800.0 2800
Example 4
A: RD Microgranules Comprising Metronidazole:
Vinylpyrrolidone-vinyl acetate copolymer (e.g., Kollidon VA 64 from BASF; 50 g) is
slowly added to a mixture of ethanol and purified water in a stainless steel container while
continuously stirring to dissolve. Next, metronidazole (180 g) is added to dissolve while stirring.
Preheated Glatt GPCG 3 is charged with deagglomerated mannitol (770 g) and crospovidone (50
g) and fluidized. The RD microgranules are prepared by spraying the solution at the following
conditions: product temperature - 34±1°C; fluidization air flow – 4 CFM; spray rate – 8-12
mL/min. Upon completion of spraying, the RD microgranules are dried for a loss on drying to
about 1% by weight.
B: RD Microgranules Comprising Clotrimazole:
Hydroxyethylcellulose (50 g) is slowly added to a mixture of ethanol and purified water
in a stainless steel container while continuously stirring to dissolve. Next, metronidazole (180 g)
is added to dissolve while stirring. Preheated Glatt GPCG 3 is charged with deagglomerated
mannitol (720 g) and crospovidone (50 g) and fluidized. The RD microgranules are prepared by
spraying the solution at the following conditions: product temperature - 34±1°C; fluidization air
206449NZ_spec_20160212_PLH
flow – 4 CFM; spray rate – 8-12 mL/min. Upon completion of spraying, the RD microgranules
are dried for a loss on drying to about 1% by weight.
C: RD Microgranules Comprising Propranolol HCl:
Vinylpyrrolidone-polyvinyl acetate copolymer (e.g., Kollidon VA 64 from BASF; 50 g)
is slowly added to purified water in a stainless steel container while continuously stirring to
dissolve. Next, propranolol HCl (240 g), a non-specific beta-blocker exhibiting extensive
hepatic metabolism, is added to dissolve while stirring. Preheated Glatt GPCG 3 is charged with
deagglomerated mannitol (560 g) and low-substituted hydroxyethylcellulose (50 g) and
fluidized. The RD microgranules are prepared by spraying the solution at the following
conditions: product temperature - 38±2°C; fluidization air flow – 10 CFM; spray rate – 10-20
mL/min. Upon completion of spraying, the RD microgranules are dried for a loss on drying to
about 1% by weight.
D. RDTs Containing Metronidazole, Clotrimazole, or Propranolol HCl
RDT tablets (Formula Ex. 4AD: Metronidazole RDTs, Formula Ex. 4BD: Clotrimazole
RDTs, and Formula Ex. 4CD: Propranolol HCl RDTs) containing required amounts of
Metronidazole RD microgranules of Ex. 4A, Clotrimazole RD microgranules of Ex. 4B, or
Propranolol HCl RD microgranules of Ex. 4C, rapidly dispersing microgranules from Ex. 1D
above at 5-15% by weight, microcrystallinecellulose (Avicel PH101 at 5-10% by weight), low-
substituted hydroxypropylcellulose at 2-5% by weight, sodium stearyl fumarate, at 1% by weight
are compressed on a Hata tablet press equipped with appropriate tooling at different compression
forces and at different turret speeds. Samples are collected at the start, mid, and end of the run
for testing for in-process tablet properties to establish the robustness of the manufacturing
processes of each tablet formulation.
The skilled artisan will recognize that the above procedures and compositions can be
suitably modified to provide the appropriate dose of drug(s) whose rapid dissolve tablet
formulations for vaginal administration are required.
While the invention has been described in connection with the specific embodiments
206449NZ_spec_20160212_PLH
herein, it will be understood that it is capable of further modifications and this application is
intended to cover any variations, uses, or adaptations of the invention following, in general, the
principles of the invention and including such departures from the present disclosure as come
within known or customary practice within the art to that the invention pertains and as may be
applied to the essential features hereinbefore set forth and as follows in the scope of the
appended claims.
All documents, patents, patent applications, and publications cited herein are
incorporated by reference in their entirety for all purposes.
206449NZ_spec_20160212_PLH
Claims (23)
1. A pharmaceutical composition in the form of a rapid dissolve vaginal tablet comprising rapid dissolve drug-containing microgranules comprising: (a) a therapeutically effective amount of a vaginally active drug; (b) 4-10% of a polymeric excipient having a dual property of acting as a binder as well as a bioadhesive material; (c) a sugar alcohol, a saccharide, or a mixture thereof; and (d) a disintegrant; wherein said pharmaceutical composition is formulated to rapidly disintegrate upon insertion into the vaginal cavity of a patient or subject forming a viscous drug-containing suspension that rapidly, widely spreads coating the vaginal mucosa.
2. The pharmaceutical composition of claim 1, wherein said vaginally active drug is selected from the group consisting of antifungal agents, antibacterial agents, antimicrobial agents, antiviral agents, anti-infectives, spermicides, steroids, hormones, analgesics including non-steroidal antiflammatory drugs, cardiovascular agents, calcium channel blockers, beta blockers, antiarrhythmics, antihypertensives, diuretics, general, coronary, peripheral and cerebral vasodilators, antimigraine agents, erectile dysfunction agents, central nervous system stimulants, sedatives, hypnotics, immunosuppressives, muscle relaxants, orally active drugs exhibiting significant first-pass effects, ß-adrenergic agonists, tranquilizers, antioxidants, vitamins, antitrichomonial agents, antiprotozoan agents, antimicoplasm agents, antiretroviral agents, nucleoside analogues, reverse transcriptase inhibitors, protease inhibitors, contraceptive agents, sulfa drugs, sulfonamides, sulfones, peptides, proteins, growth hormones, and luteinizing- hormone-releasing hormone, or mixtures or combinations thereof.
3. The pharmaceutical composition of claim 2, wherein said vaginally active drug is a reverse transcriptase inhibitor, nucleoside or nucleotide reverse transcriptase inhibitor, non-nucleotide reverse transcriptase inhibitor, protease inhibitor selected from the group consisting of apricitabine, entecavir, emtricitabine, tenofovir, abacavir, adefovir, nevirapine, delavirdine, 206449NZ_spec_20160212_PLH efavirenz, UC-781, MKC-442, quinoxaline HBY 097, DMP 266, indinavir, amprenavir, darunavir, lotinavir, nelfinavir, ritonavir, sequinavir, atazanavir, tipranavir, elvitegravir, and MK- 2048, or their pharmaceutically acceptable salts, or mixtures or combinations thereof.
4. The pharmaceutical composition of claim 2, wherein said vaginally active drug is an antifungal agent selected from the group consisting of butoconazolenystatin, oxiconazle, fluconazole, posaconazole, clotrimazole, and ketoconazole, or their pharmaceutically acceptable salts, or mixtures or combinations thereof.
5. The pharmaceutical composition of claim 2, wherein said vaginally active drug is an antibacterial agent selected from the group consisting of clindamycin, sulfonamides, erythromycin, clarithromycin, azithromycin, doxycycline, metronidazole, macrolide antibiotics, quinolones, cephalosporins, cefoxitin, and ceftriaxone, or mixtures or combinations thereof.
6. The pharmaceutical composition of claim 2, wherein said vaginally active drug is an antiviral agent selected from the group consisting of penciclovir, acyclovir, genciclovir, and valaciclovir, or mixtures or combinations thereof.
7. The pharmaceutical composition of claim 2, wherein said vaginally active drug is a cardiovascular agent selected from the group consisting of verapamil, propranolol, metoprolol, diltiazem, isradipine, felodipine, nifedipine, and nicardipine, or mixtures or combinations thereof.
8. The pharmaceutical composition of claim 2, wherein said vaginally active drug is a non-steroidal anti-inflammatory drug selected from the group consisting of aspirin, ibuprofen, indomethacin, sulindac, naproxen, and nebumetone, or mixtures or combinations thereof.
9. The pharmaceutical composition of claim 1, further comprising at least one surfactant selected from the group consisting of DL-alpha tocopherol, propylene glycol dicaprylocaprate, 206449NZ_spec_20160212_PLH Polysorbate 20, Polysorbate 80, Vitamin E TPGS, Propylene glycol monocaprylate, versions of polyethoxylated castor oil, 2-(2-ethoxyethoxy)ethanol, PEG 400, lecithin, triacetin, sodium lauryl sulfate, ethylene glycol monostearate, polysorbates, poloxamers, lauroyl polyoxylglycerides, combination of [1,3-bis(2-hydroxyethoxy)propanyloxy]ethanol; hexadecanoic acid; octadecanoic acid (apricot kernel oil PEG-6 esters and/or PEG-5 oleate), PEG-8 caprylic/capric glycerides, polyglyceryl-3 polyricinoleate, sodium lauryl salicylate, and sodium dodecyl sulfate, or mixtures thereof.
10. The pharmaceutical composition of claim 1, further comprising at least one lipid selected from the group consisting of lecithins, hydrogenated lecithins, lysolecithin, hydrogenated lysolecithins, lysophospholipids, phospholipids, salts of alkylsulfates, salts of fatty acids, sodium docusate, stearyl alcohol, glyceryl palmitostearate, mixtures of mono-, di-, and tri-esters of glycerol, mono- and di-esters of PEG, and free PEG, or mixtures thereof.
11. The pharmaceutical composition of any one of claims 1-10, further comprising a population of rapidly-dispersing microgranules each having an average particle size of not more than about 400 µm and comprising (1) a disintegrant and (2) a sugar alcohol or a saccharide, wherein said sugar alcohol or saccharide each has an average particle size of not more than about 30 μm.
12. The pharmaceutical composition of claim 11, wherein the ratio of rapid dissolve drug-containing microgranules to rapidly-dispersing microgranules ranges from about 50:1 to about 1:2.
13. The pharmaceutical composition of claim 11, wherein the rapidly-dispersing microgranules comprise a disintegrant selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked carboxymethylcellulose of sodium, and low-substituted hydroxypropylcellulose, or mixtures thereof. 206449NZ_spec_20160212_PLH
14. The pharmaceutical composition of claim 11, wherein the rapidly-dispersing microgranules comprise a sugar alcohol selected from the group consisting of arabitol, erythritol, glycerol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol, or combinations thereof.
15. The pharmaceutical composition of any one of claims 1 to 10, that disintegrates in about 60 seconds when tested by USP method <701> disintegration time.
16. The pharmaceutical composition of claim 15, further comprising rapidly-dispersing microgranules with an average particle size of not more than about 400 µm, further comprising a disintegrant and a sugar alcohol or a saccharide or a combination thereof, each having an average particle size of not more than about 30 µm, wherein said rapid dissolve tablet exhibits the following properties: i) a friability of not more than 1% by weight; and ii) sufficient tablet hardness suitable for packaging in blisters or bottles for storage, transportation, commercial distribution, and end use.
17. A method for the preparation of the pharmaceutical composition in the form of a rapid dissolve vaginal tablet comprising: a) preparing rapid dissolve drug-containing microgranules by granulating : i. at least one vaginally active drug selected from the group consisting of antifungal agents, antibacterial agents, antimicrobial agents, antiviral agents, anti-infectives, spermicides, steroids, hormones, analgesics including non-steroidal antiflammatory drugs, cardiovascular agents, calcium channel blockers, beta blockers, antiarrhythmics, antihypertensives, diuretics, general, coronary, peripheral and cerebral vasodilators, antimigraine agents, erectile dysfunction agents, central nervous system stimulants, sedatives, hypnotics, immunosuppressants, muscle relaxants, orally active drugs exhibiting significant first-pass effects, ß-adrenergic agonists, tranquilizers, antioxidants, vitamins, antitrichomonial agents, antiprotozoan agents, antimicoplasm agents, antiretroviral agents, nucleoside analogues, reverse transcriptase inhibitors, protease inhibitors, contraceptive agents, sulfa drugs, 206449NZ_spec_20160212_PLH sulfonamides, sulfones, peptides, proteins, growth hormones, and luteinizing- hormone-releasing hormone, or mixtures or combinations thereof; ii. mannitol; iii. a 4-10% polymeric excipient selected from the group consisting of low-substituted hydroxyethylcellulose, hydroxypropylcellulose, hypromellose, polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone-polyvinyl acetate copolymer, ethylene glycol 6000 - vinylcaprolactam - vinyl acetate copolymer, polyvinyl alcohol, polyethylene oxide, poly(lactic co-glycolic acid), polyamide, alginic acid salts, carrageenan, chitosan, and cellulosic gum.
18. The method of claim 17, further comprising: b) preparing rapidly dispersing microgranules comprising granulating: i. at least one sugar alcohol, saccharide, or a mixture thereof, selected from the group consisting of arabitol, erythritol, glycerol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol, orcombinations thereof; and ii. at least one disintegrant selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked carboxymethylcellulose of sodium, and low-substituted hydroxypropylcellulose, or mixtures thereof, at a ratio of 90:10 to 99:1; c) blending rapid dissolve microgranules from step a), rapidly dispersing microgranules from step b), and at least one pharmaceutically acceptable excipient selected from the group consisting of fillers, disintegrants, and lubricants selected from the group consisting of microcrystalline cellulose, crospovidone, low-substituted hydroxypropylcellulose, magnesium stearate, and sodium stearyl fumarate; and d) compressing the product of c) into rapid dissolve tablets via compressing on a rotary tablet press; wherein the rapid dissolve tablet rapidly disintegrates upon insertion into the vagina of a patient or subject in need thereof, forming a viscous drug-containing suspension that rapidly, widely spreads, coating the vaginal mucosa.
19. The method of claim 17 or 18, further comprising: 206449NZ_spec_20160212_PLH a) preparing rapid dissolve microgranules by granulating tenofovir, mannitol, low- substituted hydroxyethylcellulose, and optionally crospovidone and chitosan; b) preparing rapidly dispersing microgranules by granulating mannitol and crosspoividone having an average particle size of not more than about 30 μm; c) blending the rapid dissolve microgranules from step a), rapidly dispersing microgranules from step b) with microcrystalline cellulose, crospovidone, and sodium stearyl fumarate to form a blend; and d) compressing the blend of step c) into rapid dissolve tablets using a rotary tablet press; wherein each rapid dissolve tablet disintegrates in about 60 seconds when tested by USP method <701> disintegration time.
20. The method of claims 18 or 19 wherein step d) further comprises compressing the blend of step c) into rapid dissolve tablets using a rotary tablet press equipped with an external lubrication system to lubricate the dies and punches prior to compression with magnesium stearate.
21. The method of claim 19, wherein step a) further comprises preparing rapid dissolve microgranules comprising emtricitabine, mannitol, low-substituted hydroxyethylcellulose, and optionally crospovidone and carbopol to prepare rapid dissolve tablets containing therapeutically effective amounts of both tenofovir and emtricitabine.
22. Use of a pharmaceutical composition of any one of claims 1 to 16 in the manufacture of a medicament that is formulated for vaginal administration.
23. Use of a pharmaceutical composition of claim 1containing therapeutically effective amounts of tenofovir and emtricitabine in the manufacture of a medicament for the treatment of HIV infection. 206449NZ_spec_20160212_PLH Day I (single dose) ? 500 ^400 4-Group 2 (2 hr) • Group 3 (24 hr) --T- 4 8 12 16 20 24 Time (hr) Day 7 (daily doses) • Group 4 (2 hr) 200 - c •Group 5 (24 hr) 0 "7" ( 4 8 12 16 20 24 Time (hr) 150000 ,fab Mean Cone. ^ 125000 • Free TFV, abd. Tissue a Free TFV, urin. Tissue 100000 • Total TFV,abd. Tissue 75000 B! Total TFV.urin. Tissue c 50000 25000 B_«JI_ 2 hr 24 hr Day 1 (single dose) 150000 Mean Cone. il 125000 • Free TFV,abd. Tissue 100000 e ii Free TFV, urin. Tissue 75000 • Total TFV,abd. Tissue 50000 B! Total TFV, urin. Tissue 25000 2 hr 24 hr Day 7 (daily doses) 100000 n Day 1 (single dose) 10000 1000 0 •Predose .<u 100 • Postdose 2 hr 24 hr 10000 Day 7 (daily doses) 1000 Predose I Postdose 2 hr 24 hr FIG. 7
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481582P | 2011-05-02 | 2011-05-02 | |
US61/481,582 | 2011-05-02 | ||
PCT/US2012/036055 WO2012151237A1 (en) | 2011-05-02 | 2012-05-02 | Rapid dissolve tablet compositions for vaginal administration |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617376A NZ617376A (en) | 2016-03-31 |
NZ617376B2 true NZ617376B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012250862B2 (en) | Rapid dissolve tablet compositions for vaginal administration | |
US20180147152A1 (en) | Rapid dissolve tablet compositions for vaginal administration | |
KR101704156B1 (en) | Mixture for producing orally rapidly disintegrating tablet | |
JP3162626B2 (en) | Irbesartan-containing pharmaceutical composition | |
TWI583384B (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzi midazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
JP2015178523A (en) | low dose entecavir formulation and its use | |
JP6514702B2 (en) | Orally disintegrating tablet composition containing corticosteroids for eosinophilic esophagitis | |
NZ536046A (en) | High dosage tablet forms of imatinib mesylate | |
KR20230093401A (en) | Solid formulation composition for oral administration with enhanced disintegration property and method for preparation thereof | |
US10105365B2 (en) | Solid antiviral dosage forms | |
CA2833115A1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
US20050118256A1 (en) | Extended release alpha-2 agonist pharmaceutical dosage forms | |
JP6147711B2 (en) | Pharmaceutical composition and method for producing the same, orally disintegrating tablet and method for producing the same | |
NZ617376B2 (en) | Rapid dissolve tablet compositions for vaginal administration | |
JP2018516942A (en) | Composition of pranlukast-containing solid preparation with improved bioavailability and method for producing the same | |
JP2016098230A (en) | Novel formulation of cilostazol, quinolinone derivative used for alleviating symptom of intermittent claudication in patients with peripheral vascular disease | |
JP2016098230A5 (en) | ||
JP5648265B2 (en) | Tablet manufacturing method | |
KR20130010531A (en) | Composition of release-controlled loxoprofen | |
CZ20002675A3 (en) | Extended release tiagabine formulations with reduced side effects |